JP2007500240A5 - - Google Patents

Download PDF

Info

Publication number
JP2007500240A5
JP2007500240A5 JP2006533503A JP2006533503A JP2007500240A5 JP 2007500240 A5 JP2007500240 A5 JP 2007500240A5 JP 2006533503 A JP2006533503 A JP 2006533503A JP 2006533503 A JP2006533503 A JP 2006533503A JP 2007500240 A5 JP2007500240 A5 JP 2007500240A5
Authority
JP
Japan
Prior art keywords
tubulin
subunit
therapeutically acceptable
drug
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006533503A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007500240A (ja
Filing date
Publication date
Priority claimed from US10/447,588 external-priority patent/US20040242649A1/en
Priority claimed from US10/857,235 external-priority patent/US20050075395A1/en
Application filed filed Critical
Priority claimed from PCT/US2004/016973 external-priority patent/WO2004105794A2/en
Publication of JP2007500240A publication Critical patent/JP2007500240A/ja
Publication of JP2007500240A5 publication Critical patent/JP2007500240A5/ja
Pending legal-status Critical Current

Links

JP2006533503A 2003-05-29 2004-06-01 Ａｂｔ−７５１による持続投与レジメン Pending JP2007500240A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/447,588 US20040242649A1 (en) 2003-05-29 2003-05-29 Extended dosing regimen
US10/842,667 US20040242650A1 (en) 2003-05-29 2004-05-10 Extended dosing regimen
US10/857,235 US20050075395A1 (en) 2003-05-28 2004-05-28 Continuous dosing regimen
PCT/US2004/016973 WO2004105794A2 (en) 2003-05-29 2004-06-01 Continuous dosing regimen with abt-751

Publications (2)

Publication Number Publication Date
JP2007500240A JP2007500240A (ja) 2007-01-11
JP2007500240A5 true JP2007500240A5 (https=) 2007-06-14

Family

ID=33494089

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006533503A Pending JP2007500240A (ja) 2003-05-29 2004-06-01 Ａｂｔ−７５１による持続投与レジメン

Country Status (6)

Country Link
US (2) US20070191437A1 (https=)
EP (1) EP1644008B1 (https=)
JP (1) JP2007500240A (https=)
CA (1) CA2526385C (https=)
MX (1) MXPA05012814A (https=)
WO (1) WO2004105794A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1758592A1 (en) * 2004-05-28 2007-03-07 Abbott Laboratories Treatment of cancer in pediatric patients
MX2007008509A (es) * 2005-01-13 2007-09-04 Abbott Lab Forma cristalina 2 de n-((2z)-2-((4-hidroxifenil)imino)-1,2- dihidro-3-piridinil)-4-metoxibencenosulfonamida.
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
ES2440965T3 (es) * 2005-01-14 2014-01-31 Chemocentryx, Inc. Heteroaril-sulfonamidas y CCR2
PL2175859T3 (pl) 2007-07-12 2012-09-28 Chemocentryx Inc Skondensowane heteroarylopirydylo- i fenylo-benzenosulfonamidy jako modulatory CCR2 do leczenia zapalenia
US20170293738A1 (en) * 2016-04-08 2017-10-12 International Business Machines Corporation Cognitive Adaptation of Patient Medications Based on Individual Feedback
MX2021014356A (es) 2016-11-23 2022-11-24 Chemocentryx Inc Metodo para tratar glomeruloesclerosis segmentaria focal.
AU2018347361A1 (en) 2017-10-11 2020-04-30 Chemocentryx, Inc. Treatment of focal segmental glomerulosclerosis with CCR2 antagonists
WO2025147179A1 (ko) * 2024-01-05 2025-07-10 주식회사 큐피크바이오 튜불린 저해제를 포함하는 병용요법을 이용한 피부 질환 예방 또는 치료용 조성물
WO2025147180A1 (ko) * 2024-01-05 2025-07-10 주식회사 큐피크바이오 튜불린 저해제를 포함하는 피부 질환 예방 또는 치료용 조성물
WO2025147181A1 (ko) * 2024-01-05 2025-07-10 주식회사 큐피크바이오 튜불린 저해제를 포함하는 탈모 예방 또는 치료용 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1275922C (en) * 1985-11-28 1990-11-06 Harunobu Amagase Treatment of cancer
EP0472053B1 (en) * 1990-08-20 1998-06-17 Eisai Co., Ltd. Sulfonamide derivatives
US6500858B2 (en) * 1994-10-28 2002-12-31 The Research Foundation Of The State University Of New York Taxoid anti-tumor agents and pharmaceutical compositions thereof
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
AUPO665397A0 (en) * 1997-05-07 1997-05-29 Borody, Thomas Julius Novel therapy for constipation
US6214865B1 (en) * 1998-06-17 2001-04-10 Eisai Co., Ltd. Macrocyclic analogs and methods of their use and preparation
US20020128228A1 (en) * 2000-12-01 2002-09-12 Wen-Jen Hwu Compositions and methods for the treatment of cancer

Similar Documents

Publication Publication Date Title
EP3143995B1 (en) Rapamycin derivative for the treatment of lung cancer
JP5911929B2 (ja) 特定の癌の治療のためのｒｄｅａ１１９／ｂａｙ８６９７６６を含む組み合わせ医薬
AU5092199A (en) Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin
JP2007500240A5 (https=)
JP2007500240A (ja) Ａｂｔ−７５１による持続投与レジメン
WO2004081012A1 (ja) 抗腫瘍効果増強剤及び抗腫瘍剤
TWI598095B (zh) 治療或緩解高齡或末期癌症患者用之醫藥組合物
US11166952B2 (en) Composition including rilpivirine and method for treating tumors or cancer
JP2010106019A (ja) リマプロストを含有してなる癌化学療法に起因する末梢神経障害予防、治療および／または症状軽減剤
US20050075395A1 (en) Continuous dosing regimen
US20050267166A1 (en) Continuous dosing regimen
HK1093423B (en) Continuous dosing regimen with abt-751
HK1093423A1 (en) Continuous dosing regimen with abt-751
CN120919131A (zh) 用于治疗伴脑转移的晚期非小细胞肺癌患者的组合药物
HK1169603B (en) Pharmaceutical combinations comprising rdea119/bay 869766 for the treatment of specific cancers
HK1232469B (en) Rapamycin derivative for the treatment of lung cancer
HK1197723B (en) Treatment of solid brain tumours with a rapamycin derivative
HK1146245B (en) Treatment of solid kidney tumours with a rapamycin derivative
HK1116064B (en) Antitumor agent
HK1116064A1 (en) Antitumor agent